DOI QR코드

DOI QR Code

Adamantyl-based N-arylamide as a Novel Series of Androgen Receptor Antagonists

아다만틸을 기반한 N-아릴아미드 신규 안드로겐 수용체 길항제

  • 우병영 ((주)아모레퍼시픽 기술연구원) ;
  • 신송석 (SK바이오랜드(주)) ;
  • 홍용덕 ((주)아모레퍼시픽 기술연구원) ;
  • 주영협 ((주)아모레퍼시픽 기술연구원) ;
  • 정연수 ((주)아모레퍼시픽 기술연구원) ;
  • 이범진 (아주대학교 약학대학) ;
  • 김수동 (아주대학교 약학대학)
  • Received : 2020.03.10
  • Accepted : 2020.03.26
  • Published : 2020.03.30

Abstract

A novel series of adamantyl derivatives of N-aryl amides as androgen receptor antagonists were synthesized and their anti-androgenic activities were evaluated. The N-aryl amides containing adamantyl derivatives had more activity than those lacking adamantyl substitutions. The synergistic effect of bulkiness of the adamantyl group and modulation of electron density on the aromatic ring by pendant groups was crucial to the potent antagonism. Molecular modeling studies were performed to elucidate the interactions between ligands and receptors.

안드로겐 수용체 길항제로서 N-아릴아미드의 신규한 아다만틸 유도체들을 합성하고 항안드로겐 활성을 평가 하였다. 아다만틸 유도체를 함유하는 N-아릴아미드는 아다만틸 치환체가 없는 유도체보다 더 높은 활성을 가졌다. 아다만틸의 공간부피 및 방향족 고리에 전자밀도 상승효과를 주는 pendant 작용기들이 강력한 길항작용에 결정적인 영향을 미쳤다. 리간드와 수용체 사이의 상호 작용을 설명하기 위해 분자 모델링 연구를 수행 하였다.

Keywords

References

  1. A. A. Soderholm, P. T. Lehtovuori, and T. H. Nyronen, Three-dimensional structure-activity relationships pf nonsteroidal ligands in complex with androgen receptor ligand-binding domain, J. Med. Chem., 48(4), 917 (2005). https://doi.org/10.1021/jm0495879
  2. S. M. Singh, S. Gauthier, and F. Labrie, Androgen receptor antagonists (antiandrogens): structure-activity relationships, Curr. Med. Chem., 7(2), 211 (2000). https://doi.org/10.2174/0929867003375371
  3. L. Zhi and E. Martinborugh, Chapter 17, Selective androgen receptor modulators (SARMS), Ann. Rep. Med. Chem., 36, 169 (2001).
  4. J. T. Dalton, A. Mukherjee, Z. Zhu, L. Kirkovsky, and D. D. Miller, Discovery of nonsteroidal androgens, Biochem. Biophys. Res. Commun., 244(1), 1 (1998). https://doi.org/10.1006/bbrc.1998.8209
  5. J. J. Morris, L. R. Hughes, A. T. Glen, and P. J. Taylor, Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens, J. Med. Chem., 34(1), 447 (1991). https://doi.org/10.1021/jm00105a067
  6. S. Yamamoto, N. Matsunaga, T. Hitaka, M. Yamada, T. Hara, J. Miyazaki, T. Santou, M. Kusaka, M. Yamaoka, N. Kanzaki, S. Furuya, A. Tasaka, K. Hamamura, and M. Ito, Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists, Bioorg. Med. Chem., 20(1), 422 (2012). https://doi.org/10.1016/j.bmc.2011.10.067
  7. J. Liu, D. Obando, V. Liao, T. Lifa, and R, Codd, The many faces of the adamantyl group in drug design, Eur J Med Chem, 46(6), 1949 (2011). https://doi.org/10.1016/j.ejmech.2011.01.047
  8. J. C. Cho, H, S, Rho, Y. H, Joo, C. S. Lee, J. Lee, S. M. Ahn, J. E. Kim, S. S. Shin, Y. H. Park, K. D. Suh, and S. N. Park, Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities, Bioorg. Med. Chem. Lett., 22(12), 4159 (2012). https://doi.org/10.1016/j.bmcl.2012.04.046
  9. A. M. Badger, J. N. Bradbeer, B. Votta, J. C. Lee, J. L. Adams and D. E. Griswold, Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function, J. Pharmacol. Exp. Ther., 279(3), 1453 (1996).